$AIMJun 8, 2026, 12:33 PMAI processed
AIM reports final enrollment in Phase 2 Ampligen + Imfinzi pancreatic cancer trial; Dec 2026 CBR readout planned
AI Summary
AIM ImmunoTech says the DURIPANC Phase 2 trial of Ampligen (rintatolimod) plus AstraZeneca's durvalumab has enrolled its final patient (subject to disqualifying pre-treatment issues) and remains on track for a planned December 2026 evaluation of the primary endpoint: Clinical Benefit Rate (CBR) at 6 months. The investigator-initiated, open-label, single-center Phase 2 will enroll up to ~25 subjects and is a joint effort with AstraZeneca and Erasmus Medical Center. No efficacy data from DURIPANC were reported yet; AIM cites prior 57-patient named-patient program data showing longer median survival versus historical controls but those results are non-randomized and require confirmation in larger trials.
Positives
- Final patient enrolled in Phase 2 DURIPANC (pending disqualifying pre-treatment circumstances)
- On track for a December 2026 primary endpoint (CBR at 6 months) evaluation
- Trial is a collaboration with AstraZeneca and Erasmus and follows prior 57-patient NPP suggesting longer median survival with Ampligen monotherapy versus historical controls
Negatives
- No DURIPANC efficacy or endpoint results reported yet
- Small, open-label, single-center Phase 2 (up to ~25 subjects) limits statistical power and generalizability
- Prior NPP comparisons are non-randomized historical controls and need confirmation in randomized pivotal trials